Investors & Media
John Crowley, Chairman and CEO, Profiled in Pharmafocus May 2018
Amicus Therapeutics Chairman and CEO John Crowley speaks to Pharmafocus about the Amicus Therapeutics commitment to patients and Pledge to a Cure.
New Jersey Business Magazine Features Amicus Therapeutics and Chip Baird, Chief Financial Officer, June 2018
Chip Baird, Chief Financial Officer, speaks to New Jersey Business Magazine about Amicus Therapeutics and the biotech boom in New Jersey.
AMICUS HAS BEEN NAMED ONE OF THE 2018 BEST PLACES TO WORK IN JERSEY
NJBIZ Announces the 2018 Best Places to Work in New Jersey!
Amicus Therapeutics has been named one of the 2018 Best Places to Work in New Jersey in the medium-sized company category. This survey and awards program identifies, recognizes and honors the top places of employment in New Jersey that benefit the state’s economy, workforce and businesses.
For more information on the Best Places to Work in New Jersey program please visit www.njbiz.com/events.
Healing Beyond Disease Featured in PharmaVOICE April 2018
Amicus launches Healing Beyond Disease, a global, employee-driven initiative inspired by people living with rare diseases and their families. View article.
Dr. Jay Barth, Chief Medical Officer, Featured in Pharmavoice October 2017
A Rare Jouney: Managing the Regulatory Landscape. View Article.
JOHN CROWLEY, CHAIRMAN AND CEO, FEATURED ON FOX BUSINESS MORNINGS WTH MARIA
Amicus Therapeutics CEO John Crowley on how his fight to find a treatment for his children’s rare disease, Pompe, has driven his work in the pharmaceutical industry. View video.
JOHN CROWLEY, CHAIRMAN AND CEO, FEATURED ON CNBC
Amicus Chairman and Chief Executive Officer John Crowley says treatment for Pompe disease could be the crown jewel of the company. View video.
One Dad's 14-year Quest For Cure
By GEETA ANAND
Seven months ago, Megan Crowley made a gutsy decision: to undergo a radical surgery to straighten out her spine, which has been crippled by Pompe disease. Photo: Lexey Swall
Amicus Therapeutics CEO: Driving Science to a Cure
John Crowley, Amicus Therapeutics chairman and CEO, discusses its Fabry pill development and next generation therapy for Pompe disease, with CNBC’s Jim Cramer.
Biotechnology Requires Massive Investment: CEO John Crowley
John Crowley, CEO of Amicus Therapeutics, discusses his biotechnology business model, as well as drugs pricing.
Amicus Coo Bradley Campbell Featured In Parmavoice
Mr. Campbell discusses how engagement with rare disease advocacy groups has helped Amicus build trust with patients and families. View article.
Amicus Hosts CabaRare
Amicus hosted a CabaRare to showcase entertainers living with rare diseases in honor of Rare Disease Day 2017.
Enrique Diloné, Senior VP of Technical Operations, Featured in Pharmavoice Supply Chain Report
Dr. Diloné discusses the unique and complex challenges in getting a therapy to geographically dispersed rare disease patients. View article.